NewTimeSpace News, as of 11:14 on March 11, 2026, Medical Device ETF (159883) rose 1.00%, with the latest price at 0.51 yuan. Looking at a longer time frame, as of March 10, 2026, Medical Device ETF has cumulatively gained 1.83% over the past week. (The stocks listed above are index constituents only and do not represent specific recommendations.)

In terms of liquidity, Medical Device ETF recorded a turnover rate of 1.26% intraday, with trading volume reaching 79.2508 million yuan. Looking at a longer time frame, as of March 10, the average daily trading volume over the past month was 152 million yuan, ranking first among comparable funds.

In terms of scale, Medical Device ETF has grown by 115 million yuan over the past week, achieving significant growth and ranking 1st among 4 comparable funds in terms of new scale additions. (Data Source: Wind)

In terms of shares, Medical Device ETF has grown by 4.187 billion shares over the past 3 months, achieving significant growth and ranking 2nd among 4 comparable funds in terms of new share additions. (Data Source: Wind)

Data shows that leveraged funds continue to build positions. Medical Device ETF recorded a latest margin purchase amount of 19.1341 million yuan, with the latest financing balance reaching 242 million yuan. (Data Source: Wind)

In terms of return capability, as of March 10, 2026, since its inception, Medical Device ETF has achieved a maximum monthly return of 22.97%, a longest consecutive rising streak of 4 months, a maximum consecutive gain of 19.79%, and an average return of 4.57% during rising months. As of March 10, 2026, the annualized excess return over the benchmark for the past 2 years is 1.09%, ranking among the top 2 out of 4 comparable funds.

In terms of drawdown, as of March 10, 2026, the relative benchmark drawdown of Medical Device ETF year-to-date is 0.13%.

In terms of fees, Medical Device ETF has a management fee of 0.50% and a custody fee of 0.10%, representing a relatively low fee structure among comparable funds.

Regarding tracking accuracy, as of March 10, 2026, the 2-year tracking error of Medical Device ETF is 0.024%, representing the highest tracking accuracy among comparable funds.

It is worth noting that the CSI All Share Medical Device Index tracked by this fund is at a historically low valuation level, with the latest price-to-book ratio (PB) at 3.02x, lower than 85.1% of the time over the past 5 years, indicating outstanding valuation attractiveness.

Medical Device ETF closely tracks the CSI All Share Medical Device Index. To reflect the overall performance of securities of companies in different industries within the CSI All Share Index samples and provide analytical tools for investors, the CSI All Share Index samples are classified into 11 first-level industries, 35 second-level industries, over 90 third-level industries, and over 200 fourth-level industries according to the CSI industry classification. All securities entering each first, second, third, and fourth-level industry are then used as samples to compile the index, forming the CSI All Share Industry Indices.

Guosheng Securities stated that from publicly available information, brain-computer interface has been written into the government work report for the first time and explicitly included in the key cultivation directions for future industries, marking that this field has further ascended from frontier technology exploration to the national industrial policy support framework. For the pharmaceutical and medical technology sectors, the inclusion of brain-computer interface in future industries will help enhance market attention toward细分directions such as neuromodulation, rehabilitation robotics, implantable medical devices, and brain science cross-applications.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.